ArticleNeurochemical research2026
Role of the P2X7-Nrf2 Pathway in Hyperalgesia Induced by Chronic Compression of the Dorsal Root Ganglion.
Article in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The aim of the present study was to test the hypothesis that purinergic P2X7 receptor (P2X7) is involved in neuropathic pain by influencing the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway. The chronic compression of the dorsal root ganglion (DRG) model (hereafter termed CCD) was used to investigate the hypothesis. We analyzed the effect of P2X7 on Nrf2 activation and the expression of downstream molecules, heme oxygenase-1 (HO-1) and NAD(P)H: quinone oxidoreductase 1 (NQO1), in the DRG following CCD. We further assessed the role of extracellular signal-regulated kinases 5 (ERK5) in the development of hyperalgesia mediated by P2X7-Nrf2 pathway in CCD. In this study, phosphorylated Nrf2 (pNrf2) expression in CCD male rats was upregulated by treatment with the P2X7 agonist BzATP but reduced by administration of the P2X7 antagonist A438079. Furthermore, BzATP-induced pNrf2 upregulation was suppressed by ERK5 blockade using the antagonist BIX02189. Expression changes in HO-1 and NQO1 mirrored those of pNrf2. These results indicated that P2X7 participated in neuropathic pain that was associated with the activation of the ERK5-Nrf2 pathway in rats.
Indexed as
Identifiers
42283887What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.